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Over the past decade, process development efforts have led to attaining titers close to 3-4g/L on a routine basis 
in CHO fed-batch cultures. However, with the advent of biosimilars and the ever expanding therapeutic portfolio 
of innovator drugs, there is a growing need for enhancing the throughput of fed-batch cultures in order to meet 
the product requirements with the limited manufacturing capacity. The classical hurdle for higher productivities in 
fed-batch cultures is the sub-optimal metabolism of mammalian cells that causes accumulation of byproducts, 
including lactate and ammonia, resulting in growth inhibition.  With a robust CHO expression system, our group 
has previously demonstrated the use of a pH-linked culture glucose control strategy called HiPDOG, which 
efficiently suppresses the production of lactate and ammonia, enabling higher cell densities and productivities. 
Even under such conditions with significantly reduced accumulations of conventional inhibitors, cell growth 
eventually halts. 
 Systems biology approach was employed to these near-optimal fed-batch cultures to probe and determine 
various biochemical and biophysical factors that could be responsible for growth inhibition. Metabolomics analysis 
of CHO fed-batch cultures and add-back experiments with purified compounds led to the identification of a number 
of metabolites as novel growth inhibitors. A significant fraction of these inhibitors are intermediates or byproducts 
of cellular catabolism.  Biosynthesis and accumulation of these inhibitors was determined to be due to high levels 
of certain medium components.  Controlling the levels of these components at lower concentrations in fed-batch 
cultures led to reduced accumulations of the inhibitors, resulting in higher peak cell densities and titers.  Details 
of the novel inhibitors, their nutrient source and their effect on cell physiology, along with strategies employed to 
automatically control accumulations of these inhibitors in fed-batch processes will be discussed. 
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